HCC |
|
Sorafenib (Nexavar) |
VEGFR-2, VEGFR-3, PDGFR-β, RAF kinases |
1 |
2007 |
SHARP Asian-Pacific |
Lenvatinib (Lenvima) |
FGFR, VEGFR, PDGFR-α, RET, KIT |
1 |
2018 |
REFLECT |
Regorafenib (Stivarga) |
Tie2, VEGFR, PDGFR, FGFR |
2 |
2017 |
RESORCE |
Nivolumab (Opdivo) |
PD-1 |
2 |
2017 |
CHECKMATE-040 |
Cabozantinib (Cabometyx) |
c-Met, VEGFR-2, AXL, RET |
2 |
2018 |
CELESTIAL |
Pembrolizumab (Keytruda) |
PD-1 |
2 |
2018 |
KEYNOTE-224 |
Ramucirumab (CYRAMZA) |
VEGFR-2 |
2 |
2019 |
REACH-2 |
Nivolumab + ipilimumab (Opdivo + Yervoy) |
PD-1, CTLA-4 |
2 |
2020 |
Cohort 4 of CHECKMATE-040 |
Atezolizumab + bevacizumab |
PD-L1/VEGF |
1 |
promising |
IMbravel50 |
Tremelimumab + durvalumab |
PD-1, CTLA-4 |
1 |
promising |
NCT02519348 |
Donafenib |
VEGFR, BRAF |
1 |
promising |
NCT02645981 |
Apatinib |
VEGFR-2 |
2 |
promising |
NCT02329860 |
|
ICC |
|
Gemcitabine + cisplatin |
chemotherapy |
1 |
2010 |
ABC-02 |
Pemigatinib (Pemazyre) |
FGFR1–3 |
2 |
2020 |
FIGHT-202 |
Ivosidenib |
IDH-1/2 |
2 |
promising |
ClarlDHy |